Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders, and Cancer Genomics and Diagnostics.
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia
2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.
Physical Activity, Symptoms, Quality of Life and Exercise Program Preferences in People With Chronic Lymphocytic Leukaemia.
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline.
Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials.
Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
<i>BTK</i> and <i>PLCG2</i> remain unmutated in one-third of patients with CLL relapsing on ibrutinib
Guideline for the treatment of chronic lymphocytic leukaemia
Genetic and phenotypic attributes of splenic marginal zone lymphoma
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)